Biblio Discovery — Demo Discovery Service

6 hasil untuk "Judith Ertle"

Menampilkan 1–6 · 1,08 detik · RSS

  1. Artikel Jurnal

    The rationale and study design of two phase II trials examining the effects of BI 685509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis

    Thomas Reiberger; Annalisa Berzigotti; Jonel Trebicka dkk.

    Trials, Vol. 24 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract Background Clinically significant portal hypertension (CSPH) drives cirrhosis-related complications (i.e. hepatic decompensation). Impaired nitric oxide (NO) bioavailability promotes sinusoidal vasoconstriction, which is the initial pathomechanism of CSPH development. Activation of soluble…

  2. Artikel Jurnal Teks lengkap

    A New Model to Estimate Prognosis in Patients with Hepatocellular Carcinoma after Yttrium-90 Radioembolization

    Zhihong Weng; Judith Ertle; Shaoping Zheng dkk.

    PLoS ONE, Vol. 8 No. 12 · 2013 · Inggris · PLOS Scopus

    Aims: The current prognostic model to estimate the survival in hepatocellular carcinoma (HCC) patients treated with transarterial hepatic selective internal radiotherapy (SIRT) is not fully characterized. The aim of this study was to establish a new scoring model including assessment of both tumor…

    Juga tersedia di: DOAJ

  3. Artikel Jurnal

    Variability of transient elastography-based spleen stiffness performed at 100 Hz

    Angelo Armandi; Talal Merizian; Merle Marie Werner dkk.

    European Radiology Experimental, Vol. 7 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract Background Spleen stiffness measurement (SSM) performed by transient elastography at 100 Hz is a novel technology for the evaluation of portal hypertension in advanced chronic liver disease, but technical aspects are lacking. We aimed to evaluate the intraexamination variability of SSM and…

  4. Artikel Jurnal

    A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis

    Philip N. Newsome; Arun J. Sanyal; Guy Neff dkk.

    Nature Communications, Vol. 14 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract Non-alcoholic steatohepatitis (NASH) is a progressive, inflammatory liver disease with no approved pharmacological treatment. This Phase IIa, double-blind, placebo-controlled, multicentre trial (ClinicalTrials.gov: NCT03166735) investigated pharmacodynamics and safety of BI 1467335, an…

  5. Artikel Jurnal

    Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance

    Katherine Johnson; Peter J. Leary; Olivier Govaere dkk.

    JHEP Reports, Vol. 4 No. 2 · 2022 · Inggris · DOAJ Scopus

    Background & Aims: Serum microRNA (miRNA) levels are known to change in non-alcoholic fatty liver disease (NAFLD) and may serve as useful biomarkers. This study aimed to profile miRNAs comprehensively at all NAFLD stages. Methods: We profiled 2,083 serum miRNAs in a discovery cohort (183 cases with…